canakinumab
CACZ885U2301
Phase 3 small_molecule terminated
Quick answer
canakinumab for Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Non-small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated